Partner David Rosen was quoted in a Modern Healthcare article, “Extending EpiPen Shelf Life Could be a Relief for Patients, Costly for Mylan,” on September 22, 2016. The article discussed Mylan’s announcement to extend the shelf life of its EpiPen, currently the pricey devices must be replaced nearly every year. Rosen commented on the Food and Drug Administration regulations required to request an expiration date change, and said if the company’s data is solid, the process is pretty straightforward and objective. He continued and said the company may have changed its manufacturing process or it may be using some kind of chemical stabilizer in its epinephrine solution to prevent oxidation and lower its sensitivity to heat.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”